Study of CPTX2309 for rheumatoid arthritis and lupus
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial tests an investigational drug called CPTX2309, given intravenously, for people with moderate to severe rheumatoid arthritis or systemic lupus erythematosus. It aims to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have moderate to severe rheumatoid arthritis or systemic lupus erythematosus.
- For rheumatoid arthritis: you must have a diagnosis based on official criteria, positive rheumatoid factor or anti-CCP antibodies, and at least 6 swollen and 6 tender joints (or certain inflammation on MRI).
- For lupus: you must have a diagnosis based on official criteria, a positive ANA test (1:80 or higher), and at least one other autoantibody (anti-dsDNA or anti-Smith).
- You cannot have taken any other investigational drug or device within 30 days or 5 half-lives before starting the study.
- You must be willing to follow study rules and visit schedule.
- You cannot have certain other health problems like serious active lupus affecting the brain (except headache) or Felty's syndrome (for RA).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called LY4298445 in healthy people and in people with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA). It aims to see if the drug is safe and how the body handles it.
This study is testing an experimental medicine called PF-08154225 to see if it can help treat several autoimmune conditions, including rheumatoid arthritis, lupus, and related disorders. It might reduce disease activity or symptoms in people who have not found relief from other treatments.
This trial tests an investigational drug called AZD5492 for people with active lupus, inflammatory myositis, or rheumatoid arthritis who haven't responded well to other treatments. It aims to see if the drug is safe and how it works in the body.
This trial tests a new drug called GSK5926371 for people with certain autoimmune diseases that affect the joints, skin, and other tissues. It aims to see if the drug is safe and how well it works.
This trial tests a new mRNA treatment called HN2301 for people with autoimmune diseases like lupus, scleroderma, or rheumatoid arthritis. It aims to see if the treatment is safe and helps control the disease.
This study tests a new medicine, TQH3906, in people with systemic lupus erythematosus (SLE) who have moderate to severe disease activity. It aims to see if TQH3906 can safely reduce lupus symptoms like joint pain, skin rash, or vasculitis.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.